The clinical study performed by van Zandwijk and colleagues involves the use of a miR-16 mimic enclosed in enveloped delivery vehicles (EDV), whose surface was functionalized with antibodies specifically targeting the epidermal growth factor receptor (EGFR), over-expressed in different cancer types, including NSCLC [53]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.